BSK02: Oral Pill
BSK02™ Is the world’s first-in-class synthetic oral cancer immunotherapy. Unlike oral immunotherapies based on live attenuated bacteria/viruses, BSK02™ is based on our-newly designed T-cell activation platform, ODP™, consisting of cell-free, fully biocompatible synthetic micro-particles.
The Oral Delivery Platform (ODP) consists of synthetic and biocompatible microparticles that incorporate an optimized mixture of cancer-specific identified and validated via K.A.I-BLADE™, immuno-stimulatory compounds, and lymphatic system targeting moieties that will effectively and safely engage a powerful immunogenic response against cancer cells throughout the body. Once it passes through the small intestine, ODP™ microparticles then deliver their potent immunostimulating cargo to regional antigen presenting cells which then orchestrate a robust and specific activation of cytotoxic T-cells, resulting in an efficient, effective and potentially durable anticancer response. ODP™ combines micro/nanotechnology with cancer-specific immunotherapy to deliver a strong, safe, and efficient off-the-shelf product due to a straightforward and flexible manufacturing process that is designed to deliver a cost-effective and cancer-tailored product. The customizable multi-antigen targeting capabilities of ODP™ have been designed to fill the cumulative unmet needs of efficacy, specificity, safety and cost-effectiveness currently missing in the cancer immunotherapy field.